Equities

Noile-Immune Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4893:TYO

Noile-Immune Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)154.00
  • Today's Change-8.00 / -4.94%
  • Shares traded336.20k
  • 1 Year change-18.95%
  • Beta--
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Noile-Immune Biotech Inc is a Japan-based company mainly engaged in the development of chimeric antigen receptor T (CAR-T) cell therapy for solid tumors using proprietary technology. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The Company establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

  • Revenue in JPY (TTM)7.14m
  • Net income in JPY-782.47m
  • Incorporated2015
  • Employees25.00
  • Location
    Noile-Immune Biotech Inc6F, Ark Ginza Bldg., 7-17-2, GinzaMINATO-KU 105-0012JapanJPN
  • Phone+81 358437819
  • Websitehttps://www.noile-immune.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Human Metabolome Technologies Inc1.43bn207.06m4.12bn62.0019.65--27.542.8835.4235.42248.83--0.623710.294.9123,060,290.009.0310.5410.9813.5960.4866.6514.4817.245.13391.350.055520.988.125.405.42--33.68--
Ribomic Inc0.00-1.05bn4.67bn25.00--1.36-----23.81-23.810.0063.040.00----0.00-31.15-29.95-32.30-31.15-------2,725.9525.20--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.06bn5.16bn14.00--1.75-----27.71-27.710.0033.640.00----0.00-66.07-35.65-74.94-36.83-------1,981.18----0.0888------44.90---67.80--
D.Western Therapeutics Institute Inc419.76m-1.06bn5.75bn21.00--3.85--13.70-24.98-24.989.4827.560.19210.41942.7119,988,760.00-48.31-24.39-52.24-26.5889.7593.00-251.53-142.258.69-274.870.2606--10.09-4.07-58.82------
Carna Biosciences, Inc.579.06m-2.17bn5.94bn63.00--19.19--10.25-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
TMS Co Ltd0.00-670.20m6.50bn18.00--2.17-----15.72-15.720.0065.780.00----0.00-21.59---22.41----------23.99--0.00------31.20------
Cyfuse Biomedical KK-100.00bn-100.00bn6.83bn21.00--2.30----------298.18------------------------5.80--0.3038---10.91---48.03------
Noile-Immune Biotech Inc7.14m-782.47m7.01bn25.00--1.70--982.06-18.07-18.070.16595.160.00160.000.0668285,720.00-17.08---17.32--30.00---10,954.38--60.62--0.00---97.61--14.65------
Tsubota Laboratory Inc973.21m-172.89m7.30bn17.00--5.65--7.50-6.79-6.7937.6150.080.47330.67264.0057,247,590.00-8.410.1041-12.170.151780.2771.43-17.760.22162.89--0.05860.00101.4925.17132.08132.7026.42--
PRISM BioLab Co Ltd677.33m-833.70m7.35bn35.00--2.70--10.85-22.84-22.8418.5473.590.1779--12.5819,352,290.00-21.90---26.79--39.83---123.09------0.00--121.62--20.56------
OncoTherapy Science, Inc.784.25m-881.65m7.53bn47.00--3.52--9.61-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
Linical Co Ltd9.87bn-1.19bn7.84bn598.00--1.18--0.7946-52.52-52.52437.00267.760.6226--3.6916,505,640.00-7.482.59-13.504.1921.6129.24-12.023.74----0.258477.26-15.20-0.9283-259.37---42.014.24
Chiome Bioscience Inc593.29m-982.78m7.92bn47.00--6.95--13.35-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Medinet Co Ltd810.29m-1.36bn7.97bn107.00--2.10--9.84-5.15-5.153.0614.270.162814.023.357,572,813.00-27.37-22.42-28.82-23.6413.5417.68-168.10-173.5915.28--0.00--5.440.6867-6.67--10.06--
Chordia Therapeutics Inc0.00-1.46bn8.53bn20.00--3.58-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn9.22bn24.00--5.11--8,309.66-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Data as of Feb 13 2026. Currency figures normalised to Noile-Immune Biotech Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.